Recombinant Human MOG Protein (aa 30-149, His Tag)

Beta LifeScience SKU/CAT #: BLPSN-3400

Recombinant Human MOG Protein (aa 30-149, His Tag)

Beta LifeScience SKU/CAT #: BLPSN-3400
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Human
Accession NP_996532.2
Synonym BTN6, BTNL11, MOGIG2, NRCLP7
Background Myelin oligodendrocyte glycoprotein (MOG) is a transmembrane protein belonging to immunoglobulin superfamily, and contains an Ig-like domain followed by two potential membrane-spanning regions. MOG is expressed only in the CNS with very low content (approximately .1% total proteins) in oligodendrogliocyte membrane. Three possible functions for MOG were suggested: (a) a cellular adhesive molecule, (b) a regulator of oligodendrocyte microtubule stability, and (c) a mediator of interactions between myelin and the immune system, in particular, the complement cascade. A direct interaction might exist between the membrane-associated regions of MOG and the myelin-specific glycolipid galactocerebroside (Gal-C), and such an interaction may have important consequences regarding the membrane topology and function of both molecules. It is considered that MOG is an autoantigen capable to produce a demyelinating multiple sclerosis-like disease in experimental animals.
Description A DNA sequence encoding the extracellular domain of human MOG (NP_996532.2) (Gly 30-Tyr 149) was expressed, fused with a His tag at the C-terminus and an additional Met at the N-terminus.
Source E.coli
Predicted N Terminal Met
AA Sequence Gly 30-Tyr 149
Molecular Weight The secreted recombinant human MOG comprises 127 a.a. with a predicted molecular mass of 15 kDa. It migrates as an approximately 19 kDa band in SDS-PAGE under reducing conditions.
Purity >97% as determined by SDS-PAGE
Endotoxin Please contact us for more information.
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile PBS, pH 7.4.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function Mediates homophilic cell-cell adhesion. Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell-cell communication.; (Microbial infection) Acts as a receptor for rubella virus.
Subcellular Location [Isoform 1]: Cell membrane; Multi-pass membrane protein.; [Isoform 5]: Cell membrane; Multi-pass membrane protein.; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.; [Isoform 3]: Cell membrane; Single-pass type I membrane protein.; [Isoform 4]: Cell membrane; Single-pass type I membrane protein.; [Isoform 6]: Cell membrane; Single-pass type I membrane protein.; [Isoform 7]: Cell membrane; Single-pass type I membrane protein.; [Isoform 8]: Cell membrane; Single-pass type I membrane protein.; [Isoform 9]: Cell membrane; Single-pass type I membrane protein.
Protein Families Immunoglobulin superfamily, BTN/MOG family
Database References
Associated Diseases Narcolepsy 7 (NRCLP7)
Tissue Specificity Found exclusively in the CNS, where it is localized on the surface of myelin and oligodendrocyte cytoplasmic membranes.

Gene Functions References

  1. Anti-MOG positive patients may have manifestations that mimic neuromyelitis optica spectrum disorders but differ in their course and prognosis from anti-AQP4 positive NMOSD. PMID: 26498263
  2. Molecular Dynamics (MD) simulations were used to explore the interactions of MOG35-55 at the receptor level. PMID: 27388119
  3. Adoptive transfer of serum from anti-MOG Ab mice or of purified anti-MOG Ab 8.18C5 into naive 2D2 recipients triggered activation and expansion of T cells followed by severe and robust experimental autoimmune encephalomyelitis, suggesting that the mechanism of anti-MOG Ab-mediated opsonization of auto-antigen may indeed contribute to initiation and propagation of CNS demyelinating disease. PMID: 27022743
  4. Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis. PMID: 28125740
  5. Data show that aquaporin-4 (AQP4) and myelin-oligodendrocyte glycoprotein (MOG) autoantibodies double positive neuromyelitis optica spectrum disorder (NMOSD) patients had a multiphase disease course with a high annual relapse rate. PMID: 26920678
  6. MOG antibody associated optic neuritis tends to involve the anterior optic pathway. PMID: 26163068
  7. This study demonstrated that increased expression of mRNA of OLIG1 in ventral prefrontal white matter in major depressive disorder. PMID: 25930075
  8. In patients with idiopathic optic neuritis, 27.6% (8/29) were positive for MOG antibodies. Three of the eight MOG-positive patients showed significantly high CSF levels of myelin basic protein. Five had optic pain and three had prodromal infection. PMID: 25838512
  9. Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model. PMID: 25393803
  10. These data demonstrate a new role for myelin glycosylation in the control of immune homeostasis in the healthy human brain through the MOG-DC-SIGN homeostatic regulatory axis, which is comprised by inflammatory insults that affect glycosylation. PMID: 24935259
  11. findings suggest that immune reactions toward MOG and in particular MOG-specific antibodies may play a functional role in multiple sclerosis PMID: 22494461
  12. Patients with neuromyelitis optica spectrum disorders with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies. PMID: 24415568
  13. Bipolar I disorder and schizophrenia share a number of common genetic risk loci and susceptibility genes including the genes coding for myelin oligodendrocytes glycoprotein (MOG). PMID: 23032943
  14. We could show for the first time that a subset of aquaporin 4-IgG seronegative patients with neuromyelitis optica exhibit a MOG-IgG mediated immune response PMID: 22204662
  15. This study provides valuable information about requirements of anti-myelin oligodendrocyte glycoprotein reactivity for being regarded as a prognostic biomarker in a subtype of MS. PMID: 22093619
  16. The authors found that the human myelin oligodendrocyte glycoprotein (MOG) specifically bound to the E1 envelope glycoprotein of rubella virus, and an antibody against MOG could block rubella virus infection. PMID: 21880773
  17. A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy. PMID: 21907016
  18. The persistence or disappearance of antibodies to MOG may have prognostic relevance for acute childhood demyelination PMID: 21795651
  19. Conformational structure of the MOG-derived peptide 101-108 in solution. PMID: 20549678
  20. A mutated MOG peptide [MOG97-109] enables detection of MOG97-109-reactive T cells in multiple sclerosis patients bearing the HLA-DRB1*0401 allele. PMID: 21653833
  21. Report provides evidence that the humoral immune response against MOG in children is specific for demyelinating inflammatory CNS disorders. PMID: 21177754
  22. Persistence of MOG antibodies despite viral clearance in a high percentage of HIV-1 associated neurocognitive disorder (HAND) patients suggests ongoing neuroinflammation, possibly preventing recovery from HAND. PMID: 21083890
  23. cell surface-expressed native myelin oligodendrocyte glycoprotein nor linear epitopes have a predictive or discriminative role during the preclinical disease phase for developing clinically isolated syndrome or multiple sclerosis later in life PMID: 20685767
  24. The results of this study have observed that changes in splicing, but not expression levels, are associated with common genetic variation in the MOG gene PMID: 20800907
  25. Our study provides first evidence that the MOG G511C (Val142Leu) polymorphism might be associated with structural changes in the total white matter volumes of OCD patients. PMID: 20452030
  26. identification of T cell epitopes that are encephalitogenic and presented by B cells PMID: 11739534
  27. The B cell and T cell epitopes have been identified in rat MOG-immunized marmosets, and these sequences are observed to map primarily onto accessible regions in the model, which may explain their ability to generate potent antibody responses. PMID: 11895369
  28. A T cell reactivity pattern analysis of multiple sclerosis patients at the onset of relapse or progression shows that there is a highly immunogenic epitope for CD4+ T cells within the transmembrane/intracellular part of MOG comprising amino acids 146-154. PMID: 12077287
  29. MOG-specific antibody is critical to the initiation of MOG-induced murine experimental autoimmune encephalomyelitis PMID: 12115610
  30. polymorphisms do not provide evidence to support a significant role for MOG in multiple sclerosis susceptibility. PMID: 12149493
  31. a substantial proportion of MOG-reactive T cells from some subjects have been activated in vivo without resulting in clinical disease PMID: 12482392
  32. Human MOG is immunogenic and induces experimental autoimmune encephalomyelitis in C57BL/6 mice via an encephalitogenic B cell response to epitopes on human MOG protein that most likely cross-react with mouse determinants. PMID: 12817031
  33. Demonstration of molecular mimicry between MOG and butyrophilin suggests that exposure to this common dietary antigen may influence the composition and function of the MOG-specific autoimmune repertoire during the course of multiple sclerosis. PMID: 14688379
  34. No significant evidence for biased transmission of alleles at the (CA)n (chi2=2.430, 6 df, P=0.876) (TAAA)n (chi2=3.550, 5 df, P=0.616), C1334T (chi2=0.040, 1 df, P=0.841) and C10991T (chi2=0.154,polymorphisms in patients with schizophrenia was seen. PMID: 15660663
  35. In human brain the splice variants of MOG appear at a late stage compared to the major isoform, coincidental with myelination and myelin maturation, unlike other myelin proteins. PMID: 16903876
  36. pathogenic antibody response to native MOG in a subgroup of multiple sclerosis patients PMID: 17142321
  37. This study represents the first evidence of alternative translation products from the MOG gene. To date, it is believed that alternative splicing of MOG is limited to primates. PMID: 17402967
  38. results indicate that variation within the MOG gene is not an important independent determinant of multiple sclerosis -inherited risk in the Sardinian population PMID: 17509152
  39. MOG may be a target of Hoxd1 PMID: 17554625
  40. Our findings highlight myelin oligodendrocyte glycoprotein splicing as a factor that could be critical to the phenotypic expression of multiple sclerosis. PMID: 17573820
  41. The associations observed in Japanese and French patients, the linkage studies and the present work speak in favor of the existence of a susceptibility gene for autism in the NF1 locus. PMID: 17897745
  42. A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. PMID: 17928868
  43. although individuals with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have an increased risk of developing multiple sclerosis, this association may at least in part reflect cross-reactivity between MOG and Epstein-Barr nuclear antigen PMID: 18753473
  44. genetic polymorphism is associated with autism in Sardinian children PMID: 19167444
  45. B cell autoimmunity to this MOG is therefore most common in patients with a very early onset of MS PMID: 19687098


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed